Edwards Lifesciences (EW) – Investment Analysts’ Recent Ratings Updates

Edwards Lifesciences (NYSE: EW) has recently received a number of price target changes and ratings updates:

  • 11/16/2026 – Edwards Lifesciences had its price target raised by Wells Fargo & Company from $113.00 to $121.00. They now have an “overweight” rating on the stock.
  • 11/11/2026 – Edwards Lifesciences had its price target raised by TD Cowen from $117.00 to $121.00. They now have a “buy” rating on the stock.
  • 11/9/2026 – Edwards Lifesciences was upgraded by Weiss Ratings from “hold (c)” to “hold (c+)”.
  • 11/8/2026 – Edwards Lifesciences was upgraded by Wall Street Zen from “hold” to “buy”.
  • 11/5/2026 – Edwards Lifesciences had its “overweight” rating reaffirmed by Wells Fargo & Company. They now have a $113.00 price target on the stock, up from $100.00.
  • 11/5/2026 – Edwards Lifesciences was given a new $120.00 price target by Mizuho.
  • 11/5/2026 – Edwards Lifesciences had its price target raised by UBS Group from $110.00 to $118.00. They now have a “buy” rating on the stock.
  • 11/5/2026 – Edwards Lifesciences had its price target raised by JPMorgan Chase & Co. from $105.00 to $120.00. They now have an “overweight” rating on the stock.
  • 11/5/2026 – Edwards Lifesciences had its price target raised by Citigroup from $110.00 to $117.00. They now have a “buy” rating on the stock.
  • 11/5/2026 – Edwards Lifesciences had its price target raised by Leerink Partners from $101.00 to $112.00. They now have an “outperform” rating on the stock.
  • 11/5/2026 – Edwards Lifesciences had its price target raised by Royal Bank Of Canada from $110.00 to $115.00. They now have an “outperform” rating on the stock.
  • 11/5/2026 – Edwards Lifesciences had its price target raised by Barclays from $110.00 to $120.00. They now have an “overweight” rating on the stock.
  • 11/5/2026 – Edwards Lifesciences had its price target raised by Sanford C. Bernstein from $99.00 to $106.00. They now have a “market perform” rating on the stock.
  • 11/5/2026 – Edwards Lifesciences had its “overweight” rating reaffirmed by Piper Sandler. They now have a $115.00 price target on the stock, up from $101.00.
  • 11/5/2026 – Edwards Lifesciences had its price target raised by BTIG Research from $110.00 to $115.00. They now have a “buy” rating on the stock.
  • 11/5/2026 – Edwards Lifesciences was upgraded by Robert W. Baird from “neutral” to “outperform”. They now have a $116.00 price target on the stock.
  • 11/4/2026 – Edwards Lifesciences was given a new $113.00 price target by Truist Financial. They now have a “buy” rating on the stock.
  • 11/4/2026 – Edwards Lifesciences was upgraded by Truist Financial from “hold” to “buy”. They now have a $113.00 price target on the stock, up from $95.00.
  • 10/31/2026 – Edwards Lifesciences was downgraded by Wall Street Zen from “buy” to “hold”.
  • 10/27/2026 – Edwards Lifesciences was given a new $104.00 price target by Deutsche Bank.
  • 10/27/2026 – Edwards Lifesciences had its “buy” rating reaffirmed by TD Cowen.
  • 10/23/2026 – Edwards Lifesciences had its “outperform” rating reaffirmed by Evercore.
  • 10/17/2026 – Edwards Lifesciences was upgraded by Wall Street Zen from “hold” to “buy”.
  • 10/15/2026 – Edwards Lifesciences had its “hold (c)” rating reaffirmed by Weiss Ratings.
  • 10/15/2026 – Edwards Lifesciences had its price target lowered by Robert W. Baird from $94.00 to $90.00. They now have a “neutral” rating on the stock.
  • 10/8/2026 – Edwards Lifesciences had its “buy” rating reaffirmed by UBS Group. They now have a $110.00 price target on the stock, up from $90.00.
  • 10/7/2026 – Edwards Lifesciences was upgraded by Barclays to “strong-buy”.
  • 10/6/2026 – Edwards Lifesciences is now covered by Barclays. They set an “overweight” rating and a $110.00 price target on the stock.
  • 10/5/2026 – Edwards Lifesciences had its “buy” rating reaffirmed by Citigroup. They now have a $101.00 price target on the stock, up from $96.00.
  • 10/5/2026 – Edwards Lifesciences had its price target raised by Evercore from $100.00 to $102.00. They now have an “outperform” rating on the stock.
  • 10/2/2026 – Edwards Lifesciences had its price target raised by JPMorgan Chase & Co. from $100.00 to $105.00. They now have an “overweight” rating on the stock.
  • 9/26/2026 – Edwards Lifesciences was downgraded by Wall Street Zen from “buy” to “hold”.

Edwards Lifesciences Stock Performance

Edwards Lifesciences stock traded down $0.26 during mid-day trading on Wednesday, reaching $105.17. 3,923,115 shares of the stock traded hands, compared to its average volume of 4,531,389. The stock has a market capitalization of $60.47 billion, a PE ratio of 59.42, a price-to-earnings-growth ratio of 2.86 and a beta of 0.85. The company has a debt-to-equity ratio of 0.05, a current ratio of 4.60 and a quick ratio of 3.86. Edwards Lifesciences Corporation has a 12-month low of $74.66 and a 12-month high of $108.00. The business’s 50-day moving average is $91.13 and its 200-day moving average is $86.56.

Edwards Lifesciences (NYSE:EW – Get Free Report) last announced its earnings results on Wednesday, November 4th. The medical research company reported $0.80 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.74 by $0.06. The business had revenue of $1.72 billion for the quarter, compared to analysts’ expectations of $1.68 billion. Edwards Lifesciences had a return on equity of 16.06% and a net margin of 15.30%. The business’s revenue for the quarter was up 10.5% on a year-over-year basis. During the same period last year, the firm posted $0.67 earnings per share. As a group, sell-side analysts predict that Edwards Lifesciences Corporation will post 3.01 EPS for the current fiscal year.

Insider Buying and Selling at Edwards Lifesciences

In other news, VP Annette Brüls sold 2,644 shares of Edwards Lifesciences stock in a transaction on Friday, August 28th. The shares were sold at an average price of $89.98, for a total transaction of $237,907.12. Following the transaction, the vice president owned 17,984 shares in the company, valued at $1,618,200.32. This trade represents a 12.82% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, SVP Andrew M. Dahl sold 544 shares of Edwards Lifesciences stock in a transaction on Monday, August 31st. The stock was sold at an average price of $91.06, for a total transaction of $49,536.64. Following the transaction, the senior vice president owned 14,868 shares in the company, valued at $1,353,880.08. This represents a 3.53% decrease in their position. The SEC filing for this sale provides additional information. Over the last three months, insiders have sold 53,945 shares of company stock valued at $5,498,306. 0.31% of the stock is owned by corporate insiders.

Edwards Lifesciences is a medical technology company focused on therapies for structural heart disease and critical care. Its products include transcatheter and surgical heart valves, as well as technologies used to monitor patients during intensive care and surgery. The company traces its origins to 1958, when engineer Lowell Edwards and surgeon Albert Starr began developing an artificial heart valve. Their work led to the Starr-Edwards valve, introduced in 1960. Edwards Lifesciences is headquartered in Irvine, California, and serves clinicians and patients around the world.

Read More

Receive News & Ratings for Edwards Lifesciences Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences Corporation and related companies with MarketBeat.com's FREE daily email newsletter.